[Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Chemoradiotherapy combined with 5-fluorouracil and cisplatin have been effective for the treatment of advanced esophageal cancer, but superior treatments are needed. We prospectively analyzed the efficacy of concurrent chemoradiotherapy using oral fluoropyrimidine (S-1) and cisplatin for the treatment of advanced esophageal cancer. The treatment protocol was determined on a phase I study. The first chemoradiotherapy course consisted of 30 Gy over 3 weeks, a daily oral administration of S-1 (80 mg/m2/day) for 2 weeks, and a 24-hour infusion of cisplatin (70 mg/M2) on day 8. A second course of chemoradiotherapy was performed after an interval of 2 weeks. Seventy-one patients entered to this phase II study for five years (stage II: n=6, stage III: n=40, stage IV: n=25). All the stage II patients obtained a complete response, while 55% and 93% of the stage III patients and 20% and 76% of the stage IV patients obtained complete and partial responses, respectively. The major toxicity was myelosuppression. Eight patients (11%)developed a grade 4 leukocytopenia. The median survival times were thirty-nine months and eleven months for the stage II + stage III and stage IV patients, respectively. Chemoradiotherapy combined with S-1 and cisplatin may be a promising treatment option for advanced esophageal cancer.